HMBD-002, a non-depleting, high-affinity anti-VISTA antibody, possesses key design features enabling robust anti-tumor activity in preclinical models, positioning it as a potentially important new ...
SINGAPORE, June 26, 2025 (GLOBE NEWSWIRE) -- Hummingbird Bioscience, a biotherapeutics company discovering and developing transformative medicines for hard-to-treat diseases, today announced that it ...
This trial is looking at a new drug called HMBD-001 for solid cancers that have spread into the surrounding tissue or to another part of the body. The trial is for people who can’t have standard ...
VISTA blockade with HMBD-002 reprograms tumor associated macrophages and promotes cytotoxic T-cell response in preclinical studies HMBD-002 in combination with anti-PD-1 treatment shows enhanced ...
SAN DIEGO & HOUSTON & SINGAPORE--(BUSINESS WIRE)--Hummingbird Bioscience (“Hummingbird Bio”), a data-driven precision biotherapeutics company discovering and developing transformative biologic ...
SAN FRANCISCO and SINGAPORE, Oct. 23, 2024 (GLOBE NEWSWIRE) -- Hummingbird Bioscience, a precision biotherapeutics company discovering and developing transformative biologics for hard-to-treat ...
HOUSTON and SINGAPORE, Feb. 8, 2022 /PRNewswire/ -- Hummingbird Bioscience, an innovative clinical-stage biotech company focused on developing precision therapies against hard-to-drug targets in ...
HER3 activation is implicated in tumor progression and in acquired resistance to EGFR and HER2 therapies Study, published in Molecular Cancer Therapeutics, found HMBD-001 to be able to uniquely block ...
Percheron Therapeutics obtains exclusive worldwide rights to Hummingbird Bioscience's anti-VISTA mAb for further clinical development Hummingbird Bioscience stands to receive up to USD 290 million in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback